The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
ACTIVE_NOT_RECRUITING
Status
Conditions
- Non-small Cell Lung Cancer
Interventions
- RADIATION: definitive radiotherapy
- DRUG: induction chemo-immunotherapy
- DRUG: concurrent chemotherapy
- DRUG: Immunotheapy consolidation
- DRUG: Thymosin Alpha1
Sponsor
Sun Yat-sen University